BAAM
PTCT icon

Baker Avenue Asset Management’s PTC Therapeutics PTCT Stock Holding History

Baker Avenue Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7
Closed -$285 – 1694
2023
Q2 		$285 Hold
7
– – ﹤0.01% 1532
2023
Q1 		$339 Hold
7
– – ﹤0.01% 1549
2022
Q4 		$267 Buy
+7
New +$291 ﹤0.01% 1519

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Baker Avenue Asset Management's PTCT Position: Q3 2023 in Review

Baker Avenue Asset Management sold out of PTC Therapeutics (PTCT) in Q3 2023, closing a stake of 7 shares — an estimated $285 sold.

Baker Avenue Asset Management first reported a position in PTCT in Q4 2022 and held it in 3 quarters. The position peaked at $339 in Q1 2023. 179 funds tracked by Wall St. Rank hold PTCT as of Q3 2023.

  • Baker Avenue Asset Management reported no remaining PTC Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 7 PTC Therapeutics shares in Q3 2023, an estimated $285.
  • Baker Avenue Asset Management first reported a position in PTC Therapeutics in Q4 2022 and held it in 3 quarters.
  • Baker Avenue Asset Management's PTC Therapeutics position peaked at $339 in Q1 2023.
  • 179 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2023.

Based on Baker Avenue Asset Management's 13F filing for Q3 2023, filed 15 Nov 2023.